Foster’s hot melt extrusion technology is designed to enhance bioavailability through melt dispersion of APIs in a polymer matrix that is then ground into powder form and pressed into tablets. Foster and the UConn will collaborate to develop continuous injection molding of the tablets from the drug/polymer matrix form, eliminating the powder grinding process. They will also explore foaming technology to reduce density and increase porosity of the molded tablets to further enhance absorption.
“Roughly half of the new drugs discovered are poorly soluble and require special processing, such as hot melt extrusion, for drug delivery dose forms,” said Tony Listro, managing director at Foster Delivery Science. “By combining our expertise in hot melt extrusion and the polymer processing resources at University of Connecticut we believe we can make meaningful advancements in manufacturing and performance of formulations involving poorly water soluble drugs.”